Quantifying uncertainty in long-term care costs following introduction of new drug therapy: the impo...
Download
1 / 10

Paul McNamee, Alessandra Vanoli, Debbie Hutchings, Ian McKeith, John Bond - PowerPoint PPT Presentation


  • 140 Views
  • Uploaded on

Quantifying uncertainty in long-term care costs following introduction of new drug therapy: the importance of model choice. Paul McNamee, Alessandra Vanoli, Debbie Hutchings, Ian McKeith, John Bond. In the next 25 minutes. Aims, methods and results of the paper

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Paul McNamee, Alessandra Vanoli, Debbie Hutchings, Ian McKeith, John Bond' - calvin-fischer


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Quantifying uncertainty in long-term care costs following introduction of new drug therapy: the importance of model choice

Paul McNamee, Alessandra Vanoli, Debbie Hutchings, Ian McKeith, John Bond


In the next 25 minutes
In the next 25 minutes... introduction of new drug therapy: the importance of model choice

  • Aims, methods and results of the paper

  • Conclusions and points for discussion


Aims of the paper
Aims of the paper introduction of new drug therapy: the importance of model choice

  • To compare two approaches in modelling the net NHS costs of drug treatment for Alzheimer’s Disease

  • Application of deterministic and probabilistic modelling methods to estimate costs and explore uncertainty about likely “budget impact” to the NHS over 10 years

  • Apply these methods to 3 different policies (ALL, NG1, NG2)


Some background
Some background introduction of new drug therapy: the importance of model choice

  • AD affects a large and growing number of older people

  • Drugs are effective at slowing disease progression

  • Uncertainty over whether they are ‘cost-effective’

  • NICE recommends assessment of “budget impact” for NHS, but only partially done for AD drugs in 2001

  • Recent guidance (March 05) - treatment should no longer be prescribed for new patients


Methods 1
Methods -1 introduction of new drug therapy: the importance of model choice

  • Simulate cost impact for AD population (England and Wales)

    • ONS population data

    • MRC ageing study for AD prevalence rates

    • Systematic review of effects of treatment on cognition

    • Long term prognosis from observational studies

  • OLS and GLM regression models estimate cost effect of changes in disease progression


Methods 2 regression models

Ordinary least squares (OLS) introduction of new drug therapy: the importance of model choice

Identity link

Normal (Gaussian) distribution

Generalized Linear Model (GLM)

Log link

Gamma or Negative Binomial Distribution

Methods – 2 Regression models

N=371

dependent variable: weekly cost

Constant term allowed.

independent variables: sex, age, ADL, MMSE




Conclusions
Conclusions £

  • Drug treatment for AD likely to lead to additional costs to the NHS

  • Choice of modelling method makes a difference to magnitude of estimates


Discussion points
Discussion points £

  • A GLM framework for probabilistic analysis more likely to produce outliers

  • Lack of evidence on long term effects

  • Estimates based on 10 year old observations of costs of care

  • Estimates assume full adoption for different NICE policy decisions – but how realistic?

  • How important is the “budget impact” question to local and national decision-makers?


ad